Mianserin

A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.

Also Known As:

Networked: 322 relevant articles (28 outcomes, 44 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Weizman, Abraham: 4 articles (01/2005 - 03/2003)
2.	Goldberg, Jeffrey I: 3 articles (08/2011 - 07/2002)
3.	Poyurovsky, Michael: 3 articles (06/2004 - 03/2003)
4.	Tam, Rose: 2 articles (08/2011 - 05/2010)
5.	Kuang, Shihuan: 2 articles (08/2011 - 07/2002)
6.	Nakamura, Jun: 2 articles (04/2009 - 09/2007)
7.	Svensson, Torgny H: 2 articles (12/2005 - 09/2005)
8.	Wiker, Charlotte: 2 articles (12/2005 - 09/2005)
9.	Wadenberg, Marie-Louise: 2 articles (12/2005 - 09/2005)
10.	Linnér, Love: 2 articles (12/2005 - 09/2005)

Related Diseases

1.	Psychomotor Agitation (Akathisia) 09/01/1997 - "Seven mianserin-treated patients improved and five revealed complete disappearance of neuroleptic-induced akathisia. " 09/01/1997 - "It contrast, it appears that low-dose mianserin is therapeutically effective in acute neuroleptic-induced akathisia." 10/04/2000 - "Improvement in a patient with severe akathisia achieved by mianserin]." 06/01/2010 - "Akathisia associated with mianserin." 03/01/1999 - "Mianserin at a low dose may be a promising therapeutic option for patients with acute neuroleptic-induced akathisia."
2.	Schizophrenia (Dementia Praecox) 07/01/1992 - "These results suggest that the negative symptoms of schizophrenia are partly improved by mianserin treatment." 07/01/1992 - "1. The efficacy of mianserin as a supplement in treating chronic schizophrenia was tested by monitoring the BPRS and plasma monoamine metabolites. " 04/01/1990 - "These results suggest that the negative symptoms of schizophrenia may be improved by mianserin treatment." 03/01/2003 - "The effect of flexible doses of mianserin on cognitive deficits in a broader schizophrenia population merits further investigation." 03/01/1999 - "Thirty neuroleptic-treated patients with schizophrenia were randomly allocated in a double-blind design to receive either mianserin (15 mg/day) or placebo for five days. "
3.	Neoplasms (Cancer) 10/01/1996 - "Treatment with mianserin resulted in a significant improvement in depressive symptoms in cancer patients, and was well tolerated." 01/01/1985 - "It is concluded that mianserin is superior to placebo in reducing the severity and duration of depression which is present especially in patients with advanced cancer.(ABSTRACT TRUNCATED AT 250 WORDS)" 01/01/2000 - "The evidence is consistent across the trials, apart from 2 trials in cancer, where the "atypical" antidepressant mianserin produced significantly less dropout than placebo. " 01/01/1985 - "The efficacy and safety of mianserin were evaluated in a randomized placebo-controlled trial of 73 depressed women with cancer. " 09/01/1995 - "These results suggest that resistance to the mianserin analgesic response may occur in animals with cancer disease. "
4.	Stroke (Strokes) 04/01/1999 - "A randomised, double blind, placebo controlled study involved 100 consecutive patients under 71 years old admitted to hospital for an acute ischaemic stroke; they were enrolled to receive 60 mg/day mianserin or placebo for 1 year. " 04/01/1999 - "Mianserin treatment did not affect stroke outcome as measured by neurological status, nor did it have any influence on functional outcome as measured by Rankin scale or Barthel index. " 04/01/1999 - "(1) To test whether early prophylactic antidepressive treatment by mianserin is able to prevent poststroke depression, and (2) to discover whether mianserin as an antidepressant has any beneficial influence on the outcome of ischaemic stroke. " 01/01/2003 - "We assessed the prevalence and associations of symptoms of insomnia in patients with acute ischemic stroke, and evaluated whether mianserin as a sedative antidepressant is beneficial in the treatment of poststroke insomnia. " 02/01/1994 - "In a 6-week study the efficacy of combined treatment of imipramine plus mianserin was compared to combined treatment of desipramine plus mianserin in patients with post-stroke depression. "
5.	Depressive Disorder (Melancholia) 01/01/1985 - "Ninety-two outpatients with depressive disorders which met Research Diagnostic Criteria were treated either with mianserin or placebo in a 6-week controlled trial. " 01/01/1992 - "Practically speaking there is a conclusion: in patients whose somatic condition contraindicates, during treatment of endogenous depression, unwanted symptoms occurring after inhibition of the cholinergic receptor, the most acceptable of the three methods would be the use of mianserin or NDULECT." 01/01/1985 - "[Treatment of anxious-depressive syndromes with Mianserin hydrochloride. " 02/04/1984 - "Two patients, who were receiving therapy with mianserin for depressive disorders, developed signs of disturbed cardiac function which resolved after mianserin therapy was discontinued. " 01/01/1983 - "Clinical effects of mianserin in endogenous depression and their relationship to drug plasma level."

Related Drugs and Biologics

1.	Antidepressive Agents (Antidepressants)
2.	Serotonin (5 Hydroxytryptamine)
3.	Trazodone (Trittico)
4.	Desipramine (Pertofrane)
5.	Cyproheptadine (Periactin)
6.	Raclopride
7.	Dopamine (Intropin)
8.	Imipramine (Janimine)
9.	Antipsychotic Agents (Antipsychotics)
10.	Clomipramine (Anafranil)

Related Therapies and Procedures

1.	Nursing Care
2.	Caloric Restriction
3.	Injections
4.	Subcutaneous Injections
5.	Analgesia